These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9869199)

  • 21. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
    Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
    Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.
    Nachbaur DM; Herold M; Maneschg A; Huber H
    Ann Hematol; 1991; 62(2-3):54-8. PubMed ID: 2031968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
    Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
    Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
    Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
    Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasma interleukin-6 and interleukin-10 levels in different subtypes of lymphoma and their clinical significance].
    Wang X; Zhao HR; Gu X; Liu P; Bikmituofu H
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Aug; 31(8):1360-4. PubMed ID: 21868324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
    Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.
    el-Far M; Fouda M; Yahya R; el-Baz H
    J Physiol Biochem; 2004 Dec; 60(4):253-8. PubMed ID: 15957243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis.
    Tienhaara A; Pulkki K; Mattila K; Irjala K; Pelliniemi TT
    Br J Haematol; 1994 Feb; 86(2):391-3. PubMed ID: 8199033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mediators of inflammation correlate with microalbuminuria in patients with non-Hodgkin's lymphoma.
    Pedersen LM; Sørensen PG
    Br J Haematol; 2003 Apr; 121(2):275-9. PubMed ID: 12694249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
    Voorzanger N; Touitou R; Garcia E; Delecluse HJ; Rousset F; Joab I; Favrot MC; Blay JY
    Cancer Res; 1996 Dec; 56(23):5499-505. PubMed ID: 8968107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome.
    Pamuk GE; Turgut B; Demir M; Vural O
    J Exp Clin Cancer Res; 2006 Dec; 25(4):537-41. PubMed ID: 17310845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL).
    Jones EA; Pringle JH; Angel CA; Rees RC
    Leuk Lymphoma; 2002 Jun; 43(6):1313-21. PubMed ID: 12153001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.
    Hara T; Tsurumi H; Takemura M; Goto H; Yamada T; Sawada M; Takahashi T; Moriwaki H
    Am J Hematol; 2000 Aug; 64(4):257-61. PubMed ID: 10911377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma.
    Demir I; Akan OY; Bilgir F; Yilmaz I; Bozkaya G; Bilgir O
    Ir J Med Sci; 2024 Jun; 193(3):1201-1207. PubMed ID: 38270775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
    Ozdemir F; Aydin F; Yilmaz M; Kavgaci H; Bektas O; Yavuz MN; Yavuz AA
    J Exp Clin Cancer Res; 2004 Sep; 23(3):485-8. PubMed ID: 15595640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
    Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
    Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An improved prognostic parameter for non-Hodgkin's lymphoma based on the combination of three serum tumor markers.
    Gui W; Wang T; Wang J; Wang L; He J; Yang B; Zhao Z; Zhang H; Zhang Q
    Int J Biol Markers; 2008; 23(4):207-13. PubMed ID: 19199267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.